Our Vision In Action
Our platform enables discovery of high-quality, novel molecules more rapidly, at lower cost
Our world-class drug discovery team is leveraging our computational platform and massive computing power to advance our preclinical pipeline and a portfolio of programs in collaboration with leading biotech and pharmaceutical companies.
Pipeline
Hematological Cancers and
Solid Tumors
Gynecological Cancers and
other Solid Tumors
Relapsed / Resistant
Non-Hodgkin's Lymphoma

Collaborative Programs
We have teamed up with venture capitalists, leading academics, and biopharma companies around the globe to establish research collaborations and co-found startups. We currently have collaborative drug discovery programs with more than 10 companies.
Some of the companies include Ajax Therapeutics, Bright Angel Therapeutics, Faxian Therapeutics, Morphic Holding, Nimbus Therapeutics, Ono Pharmaceutical, Sanofi, ShouTi , Sun Pharma Advanced Research Company (SPARC), Takeda, and TB Alliance. These programs are being advanced by our collaborators in diverse therapeutic areas, including oncology, antifungals, fibrosis, inflammatory bowel disease, metabolic disease, autoimmune disease, immuno-oncology, cardiopulmonary disease, neurodegenerative disease, and tuberculosis.
These collaborations have to date resulted in two FDA approved drugs and multiple programs that have advanced into clinical trials.